-
Media Release
Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanoma
-
Media Release
Novartis investigational dual bronchodilator significantly improved lung function compared to single bronchodilators in patients with moderate-to-severe COPD in phase III studies
-
Media Release
Novartis investigational dual bronchodilator significantly improved lung function compared to single bronchodilators in patients with moderate-to-severe COPD in phase III studies
-
Media Release
Novartis announces FDA approval for Jadenu™ to simplify treatment administration for patients with chronic iron overload
-
Media Release
Novartis announces FDA approval for Jadenu™ to simplify treatment administration for patients with chronic iron overload
-
Media Release
Novartis presents Cosentyx™ two-year efficacy and safety data showing sustainable effect in psoriasis patients
-
Media Release
Novartis presents Cosentyx™ two-year efficacy and safety data showing sustainable effect in psoriasis patients
-
Media Release
New Novartis data show more Cosentyx™-treated psoriasis patients achieved clear or almost clear skin (PASI 90) compared to Stelara®
-
Media Release
New Novartis data show more Cosentyx™-treated psoriasis patients achieved clear or almost clear skin (PASI 90) compared to Stelara®
-
Media Release
Novartis' heart failure medicine LCZ696 granted FDA priority review
-
Media Release
Novartis' heart failure medicine LCZ696 granted FDA priority review
-
Media Release
Novartis announces FDA approval for first IL-17A antagonist Cosentyx™ (secukinumab) for moderate-to-severe plaque psoriasis patients